Biosimilar Updates with National Expert, Sonia Oskouei

In this episode, our guest is Our guest, Sonia Oskouei, PharmD, BCMAS, DPLA, joined Cardinal Health in June 2020 to lead the company’s biosimilar strategy. She most recently served as the Vice President of Innovation and Digital Health at Premier Inc., where she led their national biosimilars strategy on behalf of 4,000 where she partnered with pharmaceutical manufacturers and providers to create resources, and education to help health system stakeholders evaluate and adopt biosimilars.
Sonia is an established thought leader with numerous publications and currently serves on the Board of Advisors for the Center for Biosimilars. She holds a Doctor of Pharmacy from Belmont University.

Main Talking Points:
Commonly asked questions: what are biosimilars?
How they are different than generics
How long they have been approved in the U.S. (and the rest of the world)
Why are they important (eg cost savings)
Explaining the interchangeability designation + why it matters
Understanding state regulations and how that will affect pharmacist adoption
i. Plug the map!
Current market dynamics and what is on the FDA horizon for future biosimilars

Host – Hillary Blackburn, PharmD, MBA
@talktoyourpharmacist for Instagram and Facebook
@HillBlackburn Twitter